NCT04551885View on ClinicalTrials.gov

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions
Solid Tumor, Adult
Interventions
DRUG

FT516

Experimental Interventional Therapy

DRUG

Avelumab

Monoclonal antibody

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

DRUG

IL-2

Biologic response modifier

Trial Locations (3)

55455

University of Minnesota Masonic Cancer Center, Minneapolis

77030

MD Anderson Cancer Center, Houston

07601

Hackensack University Medical Center/John Theurer Cancer Center, Hackensack

Sponsors

Lead Sponsor

Fate Therapeutics
All Listed Sponsors
lead

Fate Therapeutics

INDUSTRY

NCT04551885 - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter